Work

Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

Year: 2021

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-021-04293-3

Authors: Thomas J. Semrad, Edward J. Kim, I-Yeh Gong, Tianhong Li, Scott Christensen, Mili Arora, Jonathan W. Riess, David R. Gandara, Karen Kelly

Institutions: Tahoe Forest Hospital, University of California Davis Medical Center, UC Davis Comprehensive Cancer Center, Kaiser Permanente, Kaiser Permanente Sacramento Medical Center

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Takeda Pharmaceuticals U.S.A., Takeda Oncology, National Cancer Institute

Awards: UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program, Cancer Center Support Grant P30

OpenAlex ID: W3160572483

FWCI: 1.17

Cites: 26

Cited by: 14

Related to: 10